v3.26.3
Note 1 - Summary of Significant Accounting Policies 1 (Details Textual)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 01, 2012
USD ($)
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2024
USD ($)
Aug. 31, 2023
USD ($)
Oct. 31, 2016
USD ($)
Dec. 31, 2013
USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Excluding Accrued Interest             $ 0          
Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss             117,949          
Marketable Securities   $ 0   $ 0 $ 0              
Accounts Receivable, Allowance for Credit Loss   0   0 0   0          
Accounts Receivable, after Allowance for Credit Loss   427,726 $ 302,330 427,726 427,726 $ 302,330 336,539   $ 486,772      
Accounts Receivable, after Allowance for Credit Loss, Noncurrent   48,543   48,543 48,543   95,673          
Unbilled Receivables, Current   47,130   47,130 47,130   45,757          
Inventory Write-down   31,451 133,174   301,017 347,893            
Equity Method Investments   69,560   69,560 69,560   69,560          
Equity Method Investment, Other-than-Temporary Impairment         0 0            
Payments to Acquire Notes Receivable   352,000     352,000 (0)            
Gain (Loss), Foreign Currency Transaction, before Tax   306,120 95,296   25,096 1,254,790            
Royalty, Percent of Sales 3.00%                      
Minimum Guaranteed Royalties, Income per Year $ 50,000                      
Licensing Agreement, Maximum License Fee and Milestone Payments                       $ 7,000,000
Licensing Agreement, Recognized                     $ 6,000,000  
Contract with Customer, Liability   1,135,220 1,135,616 1,135,220 1,135,220 1,135,616 1,119,788   $ 1,158,052      
Contract with Customer, Liability, Noncurrent   $ 1,085,753   $ 1,085,753 $ 1,085,753   1,085,753          
Option Indexed to Issuer's Equity, Indexed Shares (in shares) | shares   5,700,000   5,700,000 5,700,000              
Government Assistance, Nonoperating Income, Increase (Decrease)   $ 0 $ 0 $ 34,814 $ 34,814 $ 658,546            
Bioscience Innovation Grant [Member]                        
Government Assistance, Award Amount                   $ 1,158,000    
The Dutch Research and Development Act Grant [Member]                        
Government Assistance, Award Amount               $ 34,814        
Liability Warrants [Member]                        
Class of Warrant or Right, Outstanding (in shares) | shares   2,100,568   2,100,568 2,100,568              
License Agreement [Member]                        
Contract with Customer, Liability   $ 373,333   $ 373,333 $ 373,333   $ 373,333          
Customer Concentration Risk [Member] | Revenue Benchmark [Member]                        
Number of Customers         3 2            
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]                        
Concentration Risk, Percentage         41.00% 48.00%            
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member]                        
Concentration Risk, Percentage         19.00% 33.00%            
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Three [Member]                        
Concentration Risk, Percentage         19.00%              
Customer Concentration Risk [Member] | Accounts Receivable [Member]                        
Number of Customers         3   3          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]                        
Concentration Risk, Percentage         41.00%   65.00%          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]                        
Concentration Risk, Percentage         37.00%   19.00%          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]                        
Concentration Risk, Percentage         12.00%   15.00%